Evidence map›Paper›PMID 24839971›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2014

Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.

Sarah J White, Howard P Hendrickson, William T Atchley, Elizabeth M Laurenzana, W Brooks Gentry, D Keith Williams, S Michael Owens

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Substance Use in the Perinatal Period.Current psychiatry reports · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sarah J WhiteDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).
Howard P HendricksonDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).
William T AtchleyDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).
Elizabeth M LaurenzanaDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).
W Brooks GentryDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).
D Keith WilliamsDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).
S Michael OwensDepartment of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.).ORCID http://orcid.org/0000-0003-1403-2778
Pennsylvania State University · US

Funding

Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
ANTIBODY-BASED THERAPY FOR METHAMPHETAMINE ABUSER01DA011560 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI OWENS, SAMUEL MICHAEL · 1998 to 2008
$3.6M
IMMUNOTHERAPY FOR DRUG ABUSER01DA007610 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI OWENS, SAMUEL MICHAEL · 1992 to 2009
$3.4M
Mechanism-based Changes in Anti-METH Monoclonal Antibody Therapy During PregnancyF30DA029372 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI ATCHLEY, WILLIAM THOMAS · 2011 to 2013
$92k
NCATS NIH HHS UL1 TR000039NIDA NIH HHS DA07610NIDA NIH HHS DA11560NIDA NIH HHS F30 DA029372NIDA NIH HHS R01 DA007610NIDA NIH HHS R01 DA011560
6 · The paper itself

Abstract

We hypothesized that treatment of pregnant rat dams with a dual reactive monoclonal antibody (mAb4G9) against (+)-methamphetamine [METH; equilibrium dissociation rate constant (KD) = 16 nM] and (+)-amphetamine (AMP; KD = 102 nM) could confer maternal and fetal protection from brain accumulation of both drugs of abuse. To test this hypothesis, pregnant Sprague-Dawley rats (on gestational day 21) received a 1 mg/kg i.v. METH dose, followed 30 minutes later by vehicle or mAb4G9 treatment. The mAb4G9 dose was 0.56 mole-equivalent in binding sites to the METH body burden. Pharmacokinetic analysis showed baseline METH and AMP elimination half-lives were congruent in dams and fetuses, but the METH volume of distribution in dams was nearly double the fetal values. The METH and AMP area under the serum concentration-versus-time curves from 40 minutes to 5 hours after mAb4G9 treatment increased >7000% and 2000%, respectively, in dams. Fetal METH serum did not change, but AMP decreased 23%. The increased METH and AMP concentrations in maternal serum resulted from significant increases in mAb4G9 binding. Protein binding changed from ∼15% to > 90% for METH and AMP. Fetal serum protein binding appeared to gradually increase, but the absolute fraction bound was trivial compared with the dams. mAb4G9 treatment significantly reduced METH and AMP brain values by 66% and 45% in dams and 44% and 46% in fetuses (P < 0.05), respectively. These results show anti-METH/AMP mAb4G9 therapy in dams can offer maternal and fetal brain protection from the potentially harmful effects of METH and AMP.

Indexed as

AmphetamineAnimalsAntibodies, MonoclonalArea Under CurveBinding SitesBrainFemaleFetusHalf-LifeMethamphetaminePregnancyProtein BindingRatsRats, Sprague-DawleySubstance-Related DisordersAmphetamineAntibodies, MonoclonalMethamphetamine

Identifiers

PMID24839971
PMCPMC4109208
OpenAlexW2164964211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.